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0019-4832/Copyright © 2015, Cardiological So2. Physiologic basis of cardiac hypertrophy1sified into two types, either physiological or pathological.1. Introduction
Cardiac hypertrophy is a common denominator of a constel-
lation of clinical abnormalities that includes hypertension,
aortic valve stenosis, hypertrophic cardiomyopathy or even
athlete heart among others. Physiologically it happens when
these conditions make heart work harder than usual. While
cardiac hypertrophy is a compensatory phenomenon (to
minimize wall stress) and is generally symptomatically silent,
its clinical consequences arise as a result of either arrhyth-
mias or its progression to symptomatic heart failure. For
clinician it is very important not only to pick up this transition
fromhypertrophic to dilated state early but also to understand
the natural history of cardiac hypertrophy as well as to screen
for the triggers that culminate into this eventuality. For basic
scientists it is important to identify and quantitate these
triggers so that appropriate diagnostic facilities can be devel-
oped to aid the physicians in diagnosing the situation.
Currently heart failure has become an important public health
problem not only in developed but in developing world as
well. The purpose of this review is to focus on the key path-
ological and molecular triggers in the progression of cardiac
hypertrophy to failure and serve as a common ground be-
tween basic scientists and clinicians.K. Maulik).
ciety of India. All rightsCardiac hypertrophy occurs as a consequence to increased
workload and is characterized by an increase in the size of
cardiac myocyte. Conventionally cardiac hypertrophy is clas-
Physiological stimuli, like exercise and pregnancy may lead to
cardiac hypertrophy, which is characterized by normal cardiac
structure, conserved or improved cardiac function, and negli-
gible alteration in cardiac gene expression pattern. On the
other hand, the pathological hypertrophy, which occurs in
response to pressure or volume overload in various diseases, is
characterized by cardiac dysfunction, reactivation of fetal
gene program, interstitial fibrosis, and ultimately heart failure.
Therefore, revelation of various signaling pathways associated
with these two forms of hypertrophy are of paramount
importance for developing specific therapy against heart fail-
ure or preventing transition of cardiac hypertrophy to failure.
Despite its importance, our understanding of the transition
from hypertrophy to heart failure in humans is far from
adequate.3. Pathologic basis for cardiac hypertrophy2,3
Cardiac fibrosis is an important characteristic feature of
pathological hypertrophy and heart failure. It is characterized
by an increase in collagens and various other extracellular
matrix (ECM) components in the heart muscle. As we know,
ECM forms the scaffold of the heart and is composed of a
number of complex macromolecules, like collagens, elastic
fibers, etc. The ECM provides a scaffold for an organized sys-
tolic contraction of the heart from a force originally generatedreserved.
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and prevents overstretch, myocyte sliding, and tissue defor-
mation during ventricular filling within a physiological limit.
At the biochemical level, ECM also serves as modulators of
tissue growth and tissue differentiation.
Fibrosis is multi-factorial in its etio-pathogenesis and can
be stimulated by several pathological processes, like ischemia,
aging, inflammation, and various paracrine as well as auto-
crine hormones. Usually there are two types of fibrosis,
reparative fibrosis and reactive fibrosis. Reparative fibrosis
occurs due to ECM deposition during scar formation following
tissue injury or cell death, a very common phenomenon in
ischemia or aging. Reactive fibrosis, on the other hand, occurs
due to increased ECM deposition around vessels and in
interstitium due to direct stimulation of fibroblasts without
cell injury, which very commonly occurs in hypertension.
Fibrosis plays an important contributory role in deterioration
of cardiac function in the progression to heart failure.3.1. Evidence from human autopsy
Human autopsy studies have shown that the degree of cardiac
fibrosis is directly proportional to the left ventricular mass.
However beyond a certain point, a plateau is reached and
fibrosis consists of 1/3rd of the myocardial mass. This implies
that increased collagen deposition corresponds to the car-
diomyocyte hypertrophy during the initial stages of pressure
overload. So there is an enlarged ventricle with fairly normal
collagen content. This is usually referred to as the compensa-
tory phase of cardiac hypertrophy and enhanced collagen
deposition in this stage may be beneficial as the collagen ma-
trix supports the increase in muscle mass. Conversely, more
severe pressure overload for a prolonged period leads to
excessive collagen deposition or fibrosis. This adversely alters
myocardial compliance ultimately resulting in increased
myocardial stiffness.3.2. Experimental evidence of adverse consequences of
cardiac fibrosis
Impairment of electrical coupling between cardiomyocytes
has been reported in animal studies with cardiac fibrosis.
Excessive fibrosis can also cause reduction in the vascular
densitywhich can cause ischemia. Thus fibrosis can adversely
influence cardiac metabolism and ventricular function.4. Molecular mechanisms for transition4
4.1. Key sensing systems for proliferation and
transcription of ECM responsible for fibrosis
A clear knowledge is lacking about how the transition from
normal distribution of the collagen in a healthy heart to
disproportionate fibrosis in cardiac hypertrophy occurs.
However, transformation of fibroblasts into an active pheno-
type (myofibroblasts) has been long identified as a significant
factor in the development of cardiac fibrosis. Myofibroblasts
are not usually found in a healthy heart, but fibroblasts adoptstructural and molecular features of myofibroblasts in the
hypertrophied heart.
Increased levels in migration, collagen synthesis and
pro-inflammatory cytokines secretion have been reported
in fibroblasts isolated from failing myocardium. Locally
secreted growth factors, like fibroblast growth factor (FGF-
2), transforming growth factor b (TGFb), platelet-derived
growth factor and hormones, like norepinephrine, angio-
tensin II and endothelin-1 also play etiopathological role.
Out of all these, TGFb is a key regulator of ECM meta-
bolism in a wide range of organ systems, including car-
diovascular system.
TGFb evokes multiple signaling pathways in cardiac fibro-
blasts. Upon binding of TGFb to its receptor, Smads (intracel-
lular proteins that transduce extracellular signals from
transforming growth factor beta ligands to the nucleus) are
phosphorylated and translocated to the nucleus, and activate
downstream gene transcription. Thus Smad induce tran-
scription of an array of fibrosis-related genes.
The crucial role of TGFb on ECM production has been
consistently demonstrated in transgenic and knockout
mice. Cardiac fibrosis is significantly low in TGFb deficient
mice. On the other hand, both interstitial fibrosis and hy-
pertrophic growth of cardiac myocytes have been demon-
strated in transgenic mice with overexpressed TGFb.
Moreover, tranilast, an inhibitor of TGFb attenuates left
ventricular fibrosis in rats with renovascular hypertension
and in diabetic rat.
Also TGFb expression is upregulated in the human heart,
subjected to long term pressure-overload. Although various
cardiovascular abnormalities, like Marfan syndrome have
been related to mutations in TGFb, there are strong in-
dications about correlation between TGFb polymorphisms in
individuals and occurrence of ischemic heart disease. Higher
levels of serum TGFb have been reported in individuals with
this polymorphism, but whether or not these individuals have
increased cardiac fibrosis or cardiac dysfunction is not clearly
known.
Reduction in ECM protein deposition has been attributed to
the therapeutic effects of ACE inhibitors and angiotensin II
receptor blockers on the heart in clinical trials. Angiotensin II
causes induction of TGFb expression a number of organs in
kidney, vascular smooth muscle cells, and in cardiac
fibroblasts.
4.2. Modulation of cardiac fibrosis in experimental
animal models
Once fibrosis was identified as amajor etio-pathological factor
of functional impairment in heart failure, both experimental
and clinical studies have been attempted to prevent or reverse
fibrosis by pharmacological agents that either inhibit collagen
synthesis or interrupt collagen cross-linking.
4.3. Collagen metabolites as a biomarker in cardiac
diseases5
In the recent past, various clinical studies have identified
candidate biomarker compounds which have direct correla-
tion with tissue (cardiac) collagen turnover.
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Fibroblasts and myofibroblasts synthesize and secrete pro-
collagen types I and III. Structurally these are helical com-
pounds with pro-peptides at one end of the molecules. These
pro-peptides are cleaved by pro-collagen proteinases, allow-
ing the incorporation of the resulting collagen molecule into
the growing fibril. In this process, the pro-peptides are
released into the bloodstream from tissue and can be
measured. The amount of circulating pro-peptides is propor-
tional to the amount of collagen turnover (fibrosis) in tissues.
This theory has been reported to be true for some pro-peptides
studied, like terminal propeptide of pro-collagen type I (PICP).
These pro-peptides meet the criteria as indicators of collagen
synthesis, or in other words as biomarkers for fibrosis.
In some studies, a fair amount of sensitivity and specificity
was reported in predicting heart failure with preserved ejec-
tion fraction in patients with hypertensive heart disease
(HHD) with increased levels of plasma PICP. A positive corre-
lation between plasma PICP levels has been reported with
cardiac fibrosis, with LV chamber stiffness in patients with
HHD. More interestingly, plasma PICP levels changed in par-
allel with the changes in LV chamber stiffness in response to
antihypertensive therapy in patients with HHD.4.5. Plasma MMP-1 (Matrix metalloproteinases)
In patients with HHD, a higher level of MMP-1 was reported in
coronary sinus blood (directly draining from the cardiac tis-
sue) when compared with ante-cubital vein blood. Moreover,
peripheral blood lMMP-1 level was higher in patients with
HHD and heart failure. Plasma MMP-1 level is directly asso-
ciated with LV end-diastolic volume and inversely with ejec-
tion fraction in these patients. These studies suggested that
an excess of circulating MMP-1 in patients with HHD can be of
cardiac origin, in the background of steady-state production
by extra-cardiac tissues.4.6. Antifibrotic therapeutic targets
Although many experimental studies are promising in the
reversal of fibrosis, many of these putative drug candidates,
like b-amino pro-pionitrile (BAPN) (which inhibits the cross-
linking of collagen) could not be studied further in patients
of heart failure due its adverse systemic effect profile.
Another promising approach to target cardiac fibrosis,
although at present restricted to pre-clinical studies include
the use of TGFb inhibitors, which are at various stages of
development.4.7. Secreted frizzled related protein 2 (Sfrp2) and
myocardial health6
It is an interesting target being closely pursued as a potential
anti-fibrotic target.
Hamster heart exhibits marked fibrosis and it is associated
with increased expression of secreted Frizzled-related protein
2 (sFRP2). Reduced fibrosis and improved function is exhibited
in FRP2-null mice subjected to myocardial infarction.Sfrps are glycoprotein molecules and have been increas-
ingly recognized as potent regulators of cellular signaling.
They have been implicated in diverse cellular processes such
as regulation of cell fate, differentiation, proliferation, and cell
death.
4.8. Stem cell therapy7
Cell therapy is actively considered as an alternative to phar-
macotherapy in the management of cardiac diseases. Most of
these studies which have demonstrated a decline in fibrosis
are in the setting of myocardial infarction. Their efficacy
against cardiac fibrosis might be due to replacement of dead
cardiomyocytes or to the direct paracrine effects of the
transplanted stem cells on the ECM or both.
4.9. Do some established drugs have anti-fibrotic effects
in heart?
4.9.1. Torasemide8
The ability of loop diuretics (a widely used drug in heart fail-
ure) to interfere with cardiac fibrosis in chronic heart failure
(CHF) was studied in a randomized, open-label, parallel-group
pilot stud. The apparent mortality and cardiac benefits were
observed more in patients receiving torasemide than in those
receiving furosemide. The results suggest that torasemide
may have beneficial effects on the process of cardiac fibrosis
in addition to its diuretic effect. It is possible that loop di-
uretics possess different efficacies to reverse myocardial
fibrosis and reduce collagen synthesis in patients with CHF.
4.9.2. Renin angiotensi aldosterone system (RAAS)9,10
Activated RAAS is a well established risk factor for majority
of cardiovascular diseases. Modulation of the RAAS by
angiotensin-converting enzyme (ACE) inhibitors or angio-
tensin type 1 receptor (AT1R) blockers (ARBs) reduces car-
diovascular mortality and slows the progression of the
disease.
These drugs reduce the risk of cardiovascular events, pre-
venting the effects of angiotensin (Ang) II on cellular growth
and proliferation, on free radical generation and on throm-
botic pathways. Ang II also stimulates the synthesis of the
mineralo-corticoid, aldosterone. Presently it is widely
accepted that aldosterone plays an important role in vascular
toxicity and fibrosis. Aldosterone causes myocardial and
aortic fibrosis and nephrosclerosis in animal models, whereas
aldosterone receptor antagonist (spironolactone and epler-
enone) can reverse these processes.
Currently, therapeutic strategies directed towards reduc-
tion in cardiac fibrosis have mostly focused on the use of ACE
inhibitors, angiotensin II receptor antagonists, and aldoste-
rone antagonists. However, the pharmacological effects of
these drugs are rather multifaceted and many mechanisms
interact with one another.5. Conclusions
Heart failure is an important clinical and public health prob-
lem and is reaching epidemic proportions in developing
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of heart failure. The transition from cardiac hypertrophy to
cardiac dilatation (failure) is clinically very important but
poorly understood. Several molecular triggers may contribute
to this transition.Conflicts of interest
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